Lv6
2010 积分 2022-02-27 加入
A novel dual mechanism-of-action bispecific PD-1-IL-2v armed by a “βγ-only” interleukin-2 variant
11天前
已完结
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
12天前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
21天前
已完结
Navigating CAR-T cells through the solid-tumour microenvironment
1个月前
已完结
Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors
1个月前
已完结
Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer
1个月前
已完结
Clinical impact of TROP2 in non‐small lung cancers and its correlation with abnormal p53 nuclear accumulation
2个月前
已完结
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
2个月前
已完结
Glucagon-based therapy: Past, present and future
2个月前
已完结
PK and PK/PD Modeling to Inform Dosing Optimization for Pamrevlumab in Idiopathic Pulmonary Fibrosis (IPF)
4个月前
已完结
皖公网安备34019202002308
